Full text is available at the source.
Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo
Spleen-Directed mRNA Vaccine with Manganese Booster for Strong Cancer Immunity in Living Animals
AI simplified
Abstract
The spleen-targeted mRNA vaccine (Mn@mRNA-LNP) significantly boosts antitumor immunity responses.
- Mn@mRNA-LNP delivers tumor antigen-encoding mRNA and manganese adjuvant to dendritic cells in the spleen.
- This system promotes dendritic cell maturation and enhances the presentation of surface antigens.
- Cytotoxic T cell production is stimulated, contributing to antitumor effects.
- Manganese acts as a safe immune adjuvant that activates the STING signaling pathway and increases type I interferon secretion.
- Mn@mRNA-LNP effectively inhibits tumor progression in established melanoma and colon tumor models, as well as in a recurrence model.
- Combining Mn@mRNA-LNP with immune checkpoint inhibitors further enhances tumor suppression and prolongs survival in mice.
AI simplified